Market access & HTA, defined.

Health Economics and Outcomes Research (HEOR) is the applied science of measuring the value a health technology delivers to patients, health systems, and payers. It combines health economics — cost-effectiveness, budget-impact, and economic modeling — with outcomes research: comparative effectiveness, patient-reported outcomes, real-world evidence, and health-related quality of life.

For pharma, biotech, and medical device companies, HEOR translates clinical trial data into the economic and humanistic arguments that health technology assessment (HTA) agencies and payers rely on. A well-designed HEOR program generates the cost-effectiveness models, indirect treatment comparisons, and real-world outcomes data that underpin reimbursement submissions in Canada, the UK, Europe, and beyond.

HEOR sits upstream of every reimbursement decision. It defines the comparators, endpoints, time horizons, and evidence gaps that reviewers will scrutinize — and, done early, it shapes clinical development so the pivotal trial actually generates the evidence payers need.

Health Technology Assessment (HTA) is the structured, multi-disciplinary evaluation of a health technology's clinical effectiveness, safety, cost-effectiveness, and broader ethical, social, and organizational impact. HTA agencies — including CDA-AMC (formerly CADTH) and INESSS in Canada, NICE in the UK, HAS in France, G-BA/IQWiG in Germany, and PBAC in Australia — issue recommendations that inform whether public and private payers will reimburse a therapy and on what terms.

An HTA review typically compares a new pharmaceutical, biologic, or medical device against relevant comparators using systematic literature reviews, network meta-analyses, and economic models. Reviewers stress-test the sponsor's assumptions: which population is truly eligible, whether the comparator is the right one, how uncertain the survival extrapolations are, and whether the incremental cost-effectiveness ratio (ICER) falls within acceptable thresholds.

For sponsors, HTA is where clinical success and commercial access diverge. A positive regulatory approval does not guarantee reimbursement — and a poorly anticipated HTA critique can delay launch by months or years. Defensible evidence, credible economic modeling, and transparent handling of uncertainty are the difference between a positive recommendation and a request for resubmission.

Market access is the strategic and operational work of ensuring an approved therapy reaches the patients who need it — through positive HTA recommendations, reimbursement listing, formulary placement, and appropriate pricing. It sits at the intersection of clinical evidence, health economics, pricing strategy, and payer engagement.

A market access strategy for a pharmaceutical product typically covers target product profile refinement, evidence-generation planning, HTA and payer submissions, pricing and contracting (including managed-entry agreements and outcomes-based arrangements), and post-launch evidence commitments. It anticipates the questions each jurisdiction's reviewers will ask and builds a value story defensible across markets.

Effective market access is not a launch activity — it is a lifecycle discipline. Decisions made in early clinical development (choice of comparator, endpoints, subgroups) constrain what evidence is available at submission. Ongoing real-world evidence, post-launch commitments, and reassessments then determine whether initial access is maintained, expanded, or restricted over time.